The Library
The expanding role of SGLT2 inhibitors in glucose-lowering and cardio-renal protection
Tools
Tools
Tools
Brown, Emily, Wilding, John P. H. , Alam, Uazman, Barber, Thomas M., Karalliedde, Janaka and Cuthbertson, Daniel J. (2020) The expanding role of SGLT2 inhibitors in glucose-lowering and cardio-renal protection. Annals of Medicine . doi:10.1080/07853890.2020.1841281 (In Press)
|
PDF
WRAP-expanding-role-SGLT2-inhibitors-glucose-lowering-cardio-renal-protection-Barber-2020.pdf - Accepted Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (1265Kb) | Preview |
Official URL: https://doi.org/10.1080/07853890.2020.1841281
Abstract
The kidney plays a major physiological role in glucose homeostasis but also contributes to the pathophysiology of type 2 diabetes (T2D), mediated by renal sodium glucose cotransporters (SGLTs). This recognition led to development of SGLT2 inhibitors that inhibit proximal renal tubular renal glucose and sodium reabsorption. The glucoretic and natriuretic effect of SGLT2 inhibitors is associated with reductions in HbA1c levels, body weight, systolic blood pressure and triglycerides.
Major vascular complications of T2D include cardiovascular disease and chronic kidney disease (CKD). Results from several cardiovascular outcome trials (CVOTs) with these drugs have highlighted benefits in reducing major adverse cardiovascular events by 11%, reducing the risk of cardiovascular death or hospitalisation for heart failure (HF) by 23% and reducing risk of progression of renal disease by 45%. Their cardiorenal benefits are apparent across a range of eGFRs (within CKD1-3 groups) and the presence or absence of ischaemic heart disease, HF or T2D. In patients with HF with reduced ejection fraction (HFrEF), similar risk reductions in cardiovascular death and HF events are also seen; results from studies in patients with HF with preserved ejection fraction (HFpEF) are awaited. Cardiorenal benefits have been recently reported in patients with CKD, regardless of the presence or absence of T2D.
Indications for use of SGLT2 inhibitors has extended beyond glucose-lowering to a central role in cardiorenal protection. This review will first explore the mechanisms by which glycaemic control, weight loss and cardiovascular risk factors are modulated therapeutically with SGLT2 inhibitors. Subsequently we outline putative mechanisms underpinning the cardiorenal benefits seen, including in HF and CKD, in the context of completed and ongoing clinical studies. Treatment strategies with SGLT2 inhibitors in individuals with CKD or HF, with and/or without T2D are increasingly appealing. Combination therapy with complementary therapeutic agents is also explored.
| Item Type: | Journal Article | ||||||
|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > RA Public aspects of medicine R Medicine > RC Internal medicine |
||||||
| Divisions: | Faculty of Medicine > Warwick Medical School > Biomedical Sciences Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016) Faculty of Medicine > Warwick Medical School |
||||||
| Library of Congress Subject Headings (LCSH): | Diabetes, Kidneys -- Diseases, Non-insulin-dependent diabetes -- Treatment, Glucose -- Metabolism, Homeostasis | ||||||
| Journal or Publication Title: | Annals of Medicine | ||||||
| Publisher: | Taylor & Francis | ||||||
| ISSN: | 0785-3890 | ||||||
| Official Date: | 27 October 2020 | ||||||
| Dates: |
|
||||||
| Date of first compliant deposit: | 2 November 2020 | ||||||
| DOI: | 10.1080/07853890.2020.1841281 | ||||||
| Status: | Peer Reviewed | ||||||
| Publication Status: | In Press | ||||||
| Access rights to Published version: | Restricted or Subscription Access | ||||||
| Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
